New drug combo aims to cut radiation for young hodgkin patients
NCT ID NCT06563245
First seen Mar 21, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This study tests whether replacing two standard chemotherapy drugs with brentuximab vedotin can help more children and young adults (ages 2 to 34) with newly diagnosed Hodgkin lymphoma achieve a complete response early in treatment. The goal is to reduce the need for radiation therapy while maintaining high survival rates. About 96 participants will receive the new drug combination and be monitored with PET scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Children's Medical Center
RECRUITINGShanghai, China
Conditions
Explore the condition pages connected to this study.